The first evidence of NKG2D down-regulation comes from studies of Groh and co-workers on CD8+ tumor infiltrating T lymphocytes: NKG2D down-modulation was induced either upon chronic stimulation with target cells expressing the ligand MIC or with patients’ sera containing soluble MICA/B [45]. The gene discussed is KLRK1; the disease is neoplasm.